Context Therapeutics
CNTX
34 hedge funds and large institutions have $114M invested in Context Therapeutics in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 9 closing their positions.
2,005% more capital invested
Capital invested by funds: $5.43M → $114M (+$109M)
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
51.41% more ownership
Funds ownership: 24.64% → 76.05% (+51%)
36% more funds holding
Funds holding: 25 → 34 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$12.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$12.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.8M |
| 4 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$12.8M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
+$8.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.53M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$111K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$30.9K |
| 4 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
-$27.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20.8K |
CNTX Hedge Fund Activity: Q2 2024 in Review
34 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q2 2024, worth a combined $114M — up 2,005% from $5.43M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CNTX positions and 9 closed out — a net gain of 10 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $12.8M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.53M sold.
- 34 institutional investors held Context Therapeutics (CNTX) as of Q2 2024, up from 25 in Q1 2024.
- Funds reported $114M of Context Therapeutics stock for Q2 2024, up 2,005% quarter-over-quarter.
- 19 funds opened new Context Therapeutics positions in Q2 2024 and 9 closed out, a net change of +10 holders.
- The largest Context Therapeutics buyer in Q2 2024 was Avidity Partners Management, an estimated $12.8M added.
- The largest Context Therapeutics seller in Q2 2024 was Opaleye Management, an estimated $1.53M sold.
Based on aggregated 13F filings for Q2 2024.